ZW 270
Alternative Names: ZW-270Latest Information Update: 08 Jun 2023
At a glance
- Originator Zymeworks
- Class Antineoplastics; Gene therapies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Interleukin-12 expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 Apr 2023 Adverse events and pharmacodynamics data from a preclinical trial in Cancer presented at the American Association for Cancer Research (AACR-2023)
- 04 Apr 2023 Preclinical trials in Cancer in Canada (Parenteral) before April 2023
- 04 Apr 2023 Adverse events and pharmacodynamics data from a preclinical trial in Cancer presented at the American Association for Cancer Research (AACR-2023)